Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lizbeth Didriksen

Pediatrics Glen Carbon, IL Medical Doctor

NPI 1861501058 CMS profile 1278608

2160 S State Route 157, Suite B, Glen Carbon, IL 62034

Open in the dashboard

General payments

$3,930

230 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lizbeth Didriksen of Glen Carbon, IL is reported in the CMS Open Payments database as having received $3,930 across 230 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $262 16
2024 General $993 58
2023 General $897 49
2022 General $765 45
2021 General $382 24
2020 General $110 6
2019 General $521 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lizbeth Didriksen
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Lizbeth Didriksen were reported at $262. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Lizbeth Didriksen Pediatrics median Middle half National median
2019 $521 $86 $31–$183 $163
2020 $110 $49 $22–$110 $114
2021 $382 $68 $27–$158 $132
2022 $765 $77 $30–$173 $149
2023 $897 $88 $33–$190 $160
2024 $993 $94 $34–$206 $164
2025 $262 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Corium, Inc. $709 54 payments
  2. Supernus Pharmaceuticals, Inc. $658 38 payments
  3. Pfizer Inc. $320 19 payments
  4. Ironshore Pharmaceuticals Inc. $310 17 payments
  5. Merck Sharp & Dohme Corporation $300 13 payments
  6. GlaxoSmithKline, LLC. $230 13 payments
  7. Sanofi Pasteur Inc. $211 11 payments
  8. Neos Therapeutics, LP $190 10 payments
  9. Seqirus USA Inc $172 7 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $130 7 payments
  11. Other $700 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,923 229 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. Azstarys $709 54 payments
  2. QELBREE Psychology $448 31 payments
  3. GARDASIL 9 $278 12 payments
  4. VAXELIS $253 11 payments
  5. TRUMENBA $239 14 payments
  6. BEXSERO $230 13 payments
  7. COMIRNATY $223 13 payments
  8. Qelbree Viloxazine Hydrochloride $210 7 payments
  9. PREVNAR 20 $192 11 payments
  10. VYVANSE $191 11 payments
  11. Other $3,025 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record